Eris Lifesciences Acquires Velbiom's Probiotic Portfolio for Rs 50 Crore
Mumbai: Eris Lifesciences Limited has announced the acquisition of the branded probiotic business of Velbiom Probiotics Private Limited through a slump sale deal valued at Rs 50 crore.
The decision was approved during the company’s Board of Directors meeting held on March 20, 2026.
The acquisition has been executed via a Business Transfer Agreement (BTA), marking Eris Lifesciences’ strategic expansion into the growing probiotics and microbiome-based therapeutics segment. Velbiom Probiotics is recognized as a science-driven bio-therapeutics company focused on India-specific microbiome research and therapy development.
According to the disclosed details, the acquired portfolio includes a range of prebiotic and probiotic formulations targeting metabolic health, gut wellness, and women’s health. The business has demonstrated steady financial performance, reporting revenues of ₹19.64 crore in FY25, ₹17.56 crore in FY24, and ₹16.02 crore for the first nine months of FY26.
Eris Lifesciences clarified that the transaction does not involve any related party and has been conducted at arm’s length. Additionally, no shareholding exchange or special rights such as board appointments are associated with the agreement.
The company stated that the acquisition aligns with its long-term strategy to strengthen its presence in specialty and chronic therapy segments, particularly in emerging areas like microbiome-based healthcare solutions.
